PMID- 30075564
OWN - NLM
STAT- MEDLINE
DCOM- 20180810
LR  - 20230928
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 31
DP  - 2018 Aug
TI  - A retrospective study of Yiqibushenhuoxue decoction for the treatment of chronic 
      obstructive pulmonary disease.
PG  - e11684
LID - 10.1097/MD.0000000000011684 [doi]
LID - e11684
AB  - This retrospective study aimed to investigate the effect and safety of 
      Yiqibushenhuoxue decoction (YQBSHXD) for the treatment of chronic obstructive 
      pulmonary disease (COPD).This study involved 120 cases of patients with COPD. 
      These cases were assigned to an intervention group and a control group equally, 
      60 subjects each group. Patients in both groups underwent Salmeterol. In 
      addition, the cases in the intervention group also received YQBSHXD. All cases 
      received a total of 12 weeks treatment. The primary outcome of lung function was 
      measured by forced expiratory volume in 1 second (FEV1), and FEV1/forced vital 
      capacity (FVC). The secondary outcomes included severity of dyspnea on exertion, 
      evaluated by 6-minute walk test (6MWT) with measurement of 6-minute walk distance 
      (6MWD); and quality of life, assessed by the St. George's Respiratory 
      Questionnaire (SGRQ). In addition, adverse events (AEs) were also recorded in 
      this study. All outcome measurements were assessed before and after 12-week 
      treatment.After 12-week treatment, cases in the intervention group underwent 
      YQBSHXD did not show better outcome in lung function improvement, measured by the 
      FEV1 (P = .11), and FEV1/FVC (P = .15), compared with those in the control group. 
      However, YQBSHXD may help to alleviate the severity of dyspnea on exertion, as 
      measured by 6MWD (P = .03), and to improve the quality of life, as assessed by 
      the SGRQ (P < .01). Additionally, no significant differences in AEs were detected 
      between the 2 groups.The results of this study showed that YQBSHXD may help to 
      manage COPD after 12-week treatment, although the lung function has not been 
      improved.
FAU - Li, Zhuying
AU  - Li Z
AD  - Department of Respiratory Medicine, First Affiliated Hospital of Heilongjiang 
      University of Chinese Medicine Heilongjiang University of Chinese Medicine The 
      Key Laboratory of Ministry of Education in North Medicine Basic and Applied 
      Research, Heilongjiang University of Chinese Medicine Department of First 
      clinical medicine, Heilongjiang University of Chinese Medicine, Harbin, China.
FAU - Tian, Chunyan
AU  - Tian C
FAU - Wang, Xuehui
AU  - Wang X
FAU - Wang, Liqin
AU  - Wang L
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 6EW8Q962A5 (Salmeterol Xinafoate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Bronchodilator Agents/therapeutic use
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Dyspnea/*drug therapy/etiology/physiopathology
MH  - Exercise Tolerance/drug effects
MH  - Female
MH  - Forced Expiratory Volume/drug effects
MH  - Humans
MH  - Lung/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Disease, Chronic Obstructive/complications/*drug 
      therapy/physiopathology
MH  - Quality of Life
MH  - Respiratory Function Tests
MH  - Retrospective Studies
MH  - Salmeterol Xinafoate/therapeutic use
MH  - Treatment Outcome
MH  - Vital Capacity/drug effects
MH  - Walk Test/methods
MH  - Young Adult
PMC - PMC6081092
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/08/05 06:00
MHDA- 2018/08/11 06:00
PMCR- 2018/08/03
CRDT- 2018/08/05 06:00
PHST- 2018/08/05 06:00 [entrez]
PHST- 2018/08/05 06:00 [pubmed]
PHST- 2018/08/11 06:00 [medline]
PHST- 2018/08/03 00:00 [pmc-release]
AID - 00005792-201808030-00074 [pii]
AID - MD-D-18-03532 [pii]
AID - 10.1097/MD.0000000000011684 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Aug;97(31):e11684. doi: 10.1097/MD.0000000000011684.